Navigation Links
In the Psoriasis Drug Market, Continued Uptake of Janssen's Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
Date:10/21/2013

BURLINGTON, Mass., Oct. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the psoriasis drug market will experience substantial growth over the next decade as sales increase from $5.5 billion in 2012 to nearly $9.2 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Psoriasis finds that the continued uptake of Janssen's interleukin 12/23 inhibitor Stelara, which is expected to experience first-line biologic use ahead of the TNF-alpha inhibitors in the second half of the 2012-2022 forecast period, will drive sales growth. Stelara is forecast to achieve sales of $2.2 billion in 2022, accounting for 24 percent of total psoriasis sales. The launches and uptake of several emerging agents—the IL-17 inhibitors (Novartis's secukinumab, Eli Lilly's ixekizumab, and Amgen/AstraZeneca/Kyowa Hakko Kirin's brodalumab) as well as Pfizer's Janus kinase inhibitor Xeljanz—will also drive sales through 2022. 

The findings also reveal that the TNF-alpha inhibitors, particularly AbbVie/Eisai's Humira, which has displaced Amgen/Stiefel/Pfizer/Takeda's Enbrel as the preferred first-line biologic, will continue to dominate as first-line biologic agents in the first half of our forecast. However, dermatologists will increasingly turn to Stelara for their biologic-naive patients, owing to the drug's favorable risk/benefit profile. This is supported by years of postmarketing safety data and will drive sales in the second half of the 2012-2022 forecast period. Beginning in 2014, the TNF-alpha inhibitors and Stelara will experience competition from emerging biologics and oral agents with novel mechanisms of action. Although concerns about their undefined safety profiles will restrict uptake initially, the emerging IL-17 inhibitors, Xeljanz, and Merck's IL-23 inhibitor MK-3222, will increase competition within the TNF-alpha-refractory space. Celgene's oral phosphodiesterase-4 inhibitor apremilast—which is also poised to enter the market in 2014—may see use in earlier lines of therapy than the emerging biologics and Xeljanz.

"Of the emerging systemic agents, the three IL-17 inhibitors—secukinumab, ixekizumab, and brodalumab—as well as MK-3222, have shown the most impressive efficacy. The efficacy of ixekizumab and brodalumab in Phase II clinical trials appears comparable to the most effective biologic for psoriasis, Janssen/Merck/Mitsubishi Tanabe's Remicade, and Phase III clinical trial data for secukinumab suggests impressive efficacy comparable to the two other agents in this drug class," said Decision Resources Business Insights Analyst Kathryn Beane. "Nevertheless, reservations about these agents' novel mechanisms of action and relatively limited safety profiles will mean that physicians will reserve these drugs initially for patients who have failed TNF-alpha inhibitors and Stelara."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
2. Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
3. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
4. AbGenomics International has raised $9.6 million for advancing its psoriasis phase-II trials in US
5. Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
6. Flu season threat greater for people with psoriasis and psoriatic arthritis who are taking immunosuppressive drugs
7. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
8. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
9. Varying Technology and Application Trends Pep up the Mature Research Antibodies Market, Finds Frost & Sullivan
10. Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
11. For Drug Manufacturers Bringing a New Product to Market, Gaining the Support of Influential Doctors Is a Mission-Critical Priority
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2019)... Calif. (PRWEB) , ... December ... ... group Attorneys for the Rights of the Child (ARC) ( http://www.arclaw.org ) ... circumcision (VMMC) program in Africa, though only on boys mostly 15 years ...
(Date:12/9/2019)... Conn. and WALNUT CREEK, Calif. (PRWEB) , ... ... ... the nation’s leading technology-based solutions to optimize healthcare provider savings across purchased services ... Sharp is the leading healthcare provider in San Diego County with four acute ...
(Date:12/9/2019)... (PRWEB) , ... December 09, 2019 , ... ... cysts most people contend with are not ‘sebaceous,’” notes Dr. Robert Levine, a ... usually epidermoid – also called ‘epidermal’ – cysts, which have their own distinct ...
Breaking Medicine Technology:
(Date:12/14/2019)... ... December 14, 2019 , ... For two years, the only ... modular buildings. Driving into the parking lot would make you think of the temporary ... is simple. Hurricane Irma devastated the old building and the hospital carried on, first ...
(Date:12/9/2019)... , ... December 09, 2019 ... ... in innovative solutions that help food and manufacturing companies engage with their ... program. This turnkey solution helps manufacturers build a cohesive culture that is ...
(Date:12/8/2019)... ... December 08, 2019 , ... Intelligent.com, a trusted resource ... Logistics Degree Programs for 2020. The comprehensive research guide is based on an ... evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment. , ...
(Date:12/6/2019)... ... December 06, 2019 , ... In ... students in Salt Lake Community College’s (SLCC) Emergency Medical Technician (EMT) ... Chelise Schaefer—were awarded the AT&T Public Safety Hero Scholarship to support their first ...
(Date:12/6/2019)... , ... December 06, 2019 , ... TIME For ... 2019, spotlighting a mix of educational, innovative, and fun destinations that are tailored to ... of the 50 coolest places. , To assemble the list, TIME for Kids gathered ...
Breaking Medicine News(10 mins):